About This Calculator

The Irinotecan Dose Calculator is a clinical support tool designed to help healthcare professionals determine patient-specific dosing for irinotecan-based chemotherapy regimens. It calculates the Body Surface Area (BSA) using the Mosteller formula and adjusts the final dose based on critical patient factors, including UGT1A1 genotype and serum total bilirubin levels, which are known to significantly impact irinotecan metabolism and toxicity.

Outputs Explained

Upon entering the required patient data, the calculator provides the following key outputs:

• Body Surface Area (BSA): Calculated in m² from the patient's height and weight. An option to cap the BSA at 2.0 m² is available, which is a common institutional practice to mitigate toxicity in larger patients.
• Calculated Base Dose: The initial dose in mg, derived from the selected regimen's dose per m² multiplied by the patient's BSA.
• Adjustments Applied: A summary of any dose reductions applied, such as the 30% reduction for patients with the UGT1A1 *28/*28 genotype.
• Final Recommended Dose: The final calculated dose in mg, rounded to the nearest 5 mg for practical administration.
• Clinical Notes: Important warnings or contraindications related to the patient's UGT1A1 status or bilirubin levels.

How to Use This Tool

To use the calculator, follow these steps:

1. Enter Patient Vitals: Input the patient's height and weight, selecting the appropriate units (cm/in and kg/lbs).
2. Select UGT1A1 Genotype: Choose the patient's UGT1A1 status from the dropdown menu. If not tested, select "Unknown".
3. Enter Bilirubin Level: Input the patient's serum total bilirubin, selecting the correct units (mg/dL or µmol/L).
4. Choose a Regimen: Select the intended irinotecan regimen (e.g., FOLFIRI) or choose "Custom Dose" to enter a specific mg/m² value.
5. Consider BSA Capping: Check the "Cap BSA" box if institutional policy requires limiting the BSA to 2.0 m² for dose calculation.
6. Calculate: The tool will automatically calculate and display the results and any relevant clinical alerts.

Dosing Overview

Irinotecan hydrochloride dosing is primarily based on Body Surface Area (BSA). The standard starting dose varies by regimen and whether it is administered as a single agent or as part of a combination therapy. The FDA label recommends a dose reduction for patients known to be homozygous for the UGT1A1*28 allele (*28/*28, or poor metabolizers) due to an increased risk of severe neutropenia. Additionally, dose modifications are necessary for patients with elevated bilirubin levels, as irinotecan is metabolized by the liver.

Switching Regimens

If a patient's treatment plan involves switching from one irinotecan-containing regimen to another (e.g., from IFL to FOLFIRI), a new dose calculation is mandatory. Each regimen has a different standard dose in mg/m² and may have different administration schedules (e.g., weekly vs. every 3 weeks). Always use the new regimen's parameters to ensure an accurate and safe dose is calculated for the initiation of the new treatment course.

Missed Dose

This calculator does not provide guidance for missed doses. Management of a missed dose of irinotecan should be handled according to institutional protocols and in consultation with the treating oncologist. The decision to administer, delay, or skip the dose depends on the patient's overall condition, the treatment schedule, and the time elapsed since the dose was missed.

Safety Alerts

Frequently Asked Questions

What is UGT1A1 and why does it matter for irinotecan?

UGT1A1 is an enzyme responsible for metabolizing SN-38, the active metabolite of irinotecan. Genetic variations, like the *28 allele, reduce the enzyme's activity, leading to higher levels of SN-38 and increased risk of severe side effects like neutropenia and diarrhea.

What does the calculator do for a UGT1A1 *28/*28 genotype?

Based on FDA recommendations, the calculator automatically applies a 30% reduction to the base calculated dose for patients identified as poor metabolizers (*28/*28) to mitigate the risk of severe toxicity.

How does high bilirubin affect irinotecan dosing?

High bilirubin indicates impaired liver function, which is critical for clearing irinotecan. The calculator issues a warning for moderately elevated levels and a stronger alert for severely elevated levels (>3.0x ULN), as toxicity risk is substantially increased.

What is the Mosteller formula?

The Mosteller formula is a widely used method to estimate a person's Body Surface Area (BSA) from their height and weight. The formula is: BSA (m²) = √[(Height(cm) × Weight(kg)) / 3600].

Why is there an option to cap BSA at 2.0 m²?

Capping BSA is a common practice at many cancer centers to prevent potentially excessive and toxic chemotherapy doses in very large or obese patients, where BSA may not accurately reflect metabolic clearance.

What is FOLFIRI?

FOLFIRI is a combination chemotherapy regimen that includes folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. The calculator includes the standard irinotecan dose for this regimen (180 mg/m²).

Can I use this calculator for pediatric patients?

No. This tool is designed based on adult dosing guidelines and protocols. The safety and effectiveness of irinotecan in pediatric patients may require different dosing considerations and should be managed by a pediatric oncologist.

What should I do if the calculated dose seems incorrect?

Always double-check your input values for accuracy. This tool is for informational purposes and should not replace clinical judgment. All calculated doses must be verified against the official prescribing information, institutional protocols, and the patient's clinical context.

References

1. Irinotecan Hydrochloride Injection - Prescribing Information (FDA)
2. DailyMed - Irinotecan Hydrochloride
3. European Medicines Agency (EMA) - Irinotecan Information
4. Innocenti F, et al. (2009). The role of UGT1A1 in irinotecan-induced neutropenia: a comprehensive analysis. PubMed, Clinical Pharmacology & Therapeutics, 86(1), 108-112.